Bayer’s latest round of layoffs has hit Basel, Switzerland, home of the international headquarters of the company's consumer health division. nnlatest round of layoffs has hit Basel, Switzerland, home of the international headquarters of the company's consumer health division.
The Journal of American Medical Association (JAMA) publishes Elinzanetant Phase III data
Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients With Chronic Kidney Disease
Perrigo announced Monday that it has added a brand-new position to its C-suite: chief brand and digital officer, an executive VP role. First to take on the title is David Ball, Ph.D., who will be tasked with heading up the company’s overall marketing strategy, including exploring new areas of opportunity in the market and building out its consumer-facing branding work.
won a legal victory in its fight to limit liability from claims that its Roundup weed killer causes cancer, as a U.S. appeals court on Thursday said federal law shields the German company from a lawsuit by a Pennsylvania landscaper.
At Bayer, a groupwide restructuring is being rolled out as a top priority. But, to Juergen Eckhardt, M.D., who leads both the investment arm Leaps by Bayer and the pharma business development team, the ongoing overhaul won’t disrupt the German company’s dealmaking appetite.
Pharmaceutical giant Bayer has teamed up with software group Alara Imaging in a bid to help standardize radiation doses used in computed tomography (CT) scans.
Bayer’s transformation under CEO Bill Anderson has picked up momentum. In reporting second-quarter earnings on Tuesday, the company revealed it has cut 3,200 jobs since the start of this year.
Amid Bayer's massive reorganization, the company's pharma group is moving full steam ahead toward market expansions for key products. nnConsidering blood thinner Xarelto's 11% sales decline during the second quarter, those expansions are becoming all the more important. As Bayer's Xarelto falls prey to generics, the drugmaker is putting more weight behind oncology blockbuster hopeful Nubeqa and ophthalmology mainstay Eylea, among other meds.
Bayer’s Kerendia was approved in 2021 to treat patients with chronic kidney disease (CKD) associated with Type 2 diabetes. For the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) to accomplish the company’s gaudy sales target however, it will have to show its chops in heart failure (HF).